Shilpa Medicare Records Highest Ever Revenue of ₹1,549 Crore in FY26

Shilpa Medicare Limited announced its full-year financial results for the period ending March 31, 2026, reporting a record annual revenue of ₹1,549 crore and quarterly revenue of ₹439 crore.

Key Highlights

Shilpa Medicare's full-year revenue for FY26 reached ₹1,549 crore, showing an 18% increase year-over-year. In the fourth quarter of FY26, revenues grew by 30% year-over-year to ₹439 crore. The company reported a full-year EBITDA of ₹445 crore, with EBITDA margins improving to 29%. Adjusted Profit After Tax (PAT) for the full year was ₹232 crore.

Crucially, the company is prioritizing the expansion of its Contract Development and Manufacturing Organization (CDMO) and biologics businesses. Shilpa Medicare also completed the sale of a 31% stake in Sravathi Advance, which resulted in an exceptional gain of ₹30 crore.

Driving Future Growth

This record revenue highlights Shilpa Medicare's consistent growth, fueled by its core API and formulation divisions, as well as its developing biologics segment. The enhanced EBITDA margins suggest improved operational efficiency and profitability. By concentrating on CDMO and biologics, Shilpa Medicare is moving toward offering more complex, high-value services that could spur future expansion and better profit margins.

Financial Performance and Strategy

In the previous fiscal year, FY25, Shilpa Medicare reported revenues of ₹1,313 crore and EBITDA of ₹323 crore. The company has been actively investing in its manufacturing infrastructure, including its Jadcherla facility, which has recently undergone audits. The divestment of a stake in Sravathi Advance is part of a broader portfolio strategy.

The company's intensified focus on and investment in CDMO and biologics are expected to become substantial drivers for revenue and profit. The improved Adjusted Return on Capital Employed (ROCE) to 17.4% reflects more efficient use of capital. Shilpa Medicare financed its capital expenditure of ₹361 crore primarily through internal funds, maintaining a net debt of ₹613 crore.

Potential Risks

Ongoing efforts to address observations from USFDA audits at the Jadcherla facility present a key regulatory consideration. Future increases in raw material prices, especially for materials and solvents, could also impact input costs and profit margins.

Competitive Landscape

Although specific FY26 financial data for direct competitors is not yet available, Shilpa Medicare's 18% year-over-year revenue growth positions it strongly within the pharmaceutical industry. Key players in the API, formulation, CDMO, and biologics markets include Divi's Laboratories, Laurus Labs, and Biocon.

Key Financial Metrics (FY26)

• Full Year Revenue: ₹1,549 crore (18% YoY growth)
• Q4 Revenue: ₹439 crore (30% YoY growth)
• Full Year EBITDA: ₹445 crore (29% margin)
• Full Year Adjusted PAT: ₹232 crore
• Net Debt: ₹613 crore
• Capital Expenditure: ₹361 crore
• Adjusted ROCE: 17.4%

Next Steps for Investors

Investors will be closely watching how Shilpa Medicare resolves USFDA audit observations, the progress in scaling its CDMO and biologics pipeline, and its ability to manage fluctuating raw material costs. Profitability from associated entities, such as 'Maaia', will also be a key area of focus.